Literature DB >> 22412232

Prolonged QTc interval and torsades de pointes induced by citalopram.

Anand Deshmukh1, Kyle Ulveling, Venkata Alla, Hussam Abuissa, Kelly Airey.   

Abstract

Citalopram is a selective serotonin reuptake inhibitor with a favorable cardiac-safety profile. Corrected QT interval (QTc) prolongation and cardiac arrhythmias have not been previously reported in association with citalopram use except in the presence of overdose, abnormal electrolyte values, or renal or liver failure. Herein, we report the case of a 40-year-old woman with mental depression who presented with a prolonged QTc interval and torsades de pointes after the initiation of citalopram at therapeutic doses. The QTc interval improved when citalopram therapy was discontinued. We recommend that clinicians investigate the family history for sudden deaths and perform baseline electrocardiography before prescribing citalopram. We also recommend routine electrocardiographic testing during citalopram therapy, and that patients with long QT syndrome avoid taking citalopram.

Entities:  

Keywords:  Citalopram/adverse effects/therapeutic use; depression/drug therapy; long QT syndrome/chemically induced/diagnosis/physiopathology; serotonin uptake inhibitors/adverse effects/therapeutic use; torsades de pointes/chemically induced/diagnosis/physiopathology

Mesh:

Substances:

Year:  2012        PMID: 22412232      PMCID: PMC3298934     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  10 in total

1.  Fatality caused by a combined trimipramine-citalopram intoxication.

Authors:  F Musshoff; P Schmidt; B Madea
Journal:  Forensic Sci Int       Date:  1999-12-06       Impact factor: 2.395

2.  Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.

Authors:  Harry J Witchel; Vijay K Pabbathi; Giovanna Hofmann; Ashok A Paul; Jules C Hancox
Journal:  FEBS Lett       Date:  2002-02-13       Impact factor: 4.124

3.  Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease.

Authors:  Cesare de Gregorio; Gaetano Morabito; Marco Cerrito; Giuseppe Dattilo; Giuseppe Oreto
Journal:  Int J Cardiol       Date:  2009-06-21       Impact factor: 4.164

4.  Fatal overdose with citalopram.

Authors:  M Oström; A Eriksson; J Thorson; O Spigset
Journal:  Lancet       Date:  1996-08-03       Impact factor: 79.321

5.  Symptoms and signs of severe citalopram overdose.

Authors:  L Grundemar; B Wohlfart; C Lagerstedt; F Bengtsson; G Eklundh
Journal:  Lancet       Date:  1997-05-31       Impact factor: 79.321

6.  Citalopram toxicity.

Authors:  M Personne; H Persson; E Sjöberg
Journal:  Lancet       Date:  1997-08-16       Impact factor: 79.321

Review 7.  Citalopram in the treatment of depression and other potential uses in psychiatry.

Authors:  J Y Tan; G M Levin
Journal:  Pharmacotherapy       Date:  1999-06       Impact factor: 4.705

8.  QTc interval prolongation associated with citalopram overdose: a case report and literature review.

Authors:  G Catalano; M C Catalano; M A Epstein; P E Tsambiras
Journal:  Clin Neuropharmacol       Date:  2001 May-Jun       Impact factor: 1.592

9.  Torsade de pointes induced by citalopram and amiodarone.

Authors:  A Fayssoil; J Issi; M Guerbaa; J-C Raynaud; V Heroguelle
Journal:  Ann Cardiol Angeiol (Paris)       Date:  2011-01-20

10.  Citalopram induced torsade de pointes, a rare life threatening side effect.

Authors:  Somsupha Kanjanauthai; Tony Kanluen; Panithaya Chareonthaitawee
Journal:  Int J Cardiol       Date:  2007-10-04       Impact factor: 4.164

  10 in total
  14 in total

Review 1.  Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics.

Authors:  Simon W Rabkin
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

Review 2.  [Therapy of dementia with antipsychotics and antidepressives].

Authors:  L Frölich; L Hausner
Journal:  Nervenarzt       Date:  2015-04       Impact factor: 1.214

Review 3.  [Ventricular tachyarrhythmia as a side effect of pharmacotherapy].

Authors:  Thomas Demming; Hendrik Bonnemeier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-09

4.  Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Authors:  Christopher Kogut; Ericka Breden Crouse; W Victor R Vieweg; Mehrul Hasnain; Adrian Baranchuk; Geneviève C Digby; Jayanthi N Koneru; Antony Fernandez; Anand Deshmukh; Jules C Hancox; Ananda K Pandurangi
Journal:  Ther Adv Drug Saf       Date:  2013-10

Review 5.  Citalopram and cardiac toxicity.

Authors:  M J Cooke; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

Review 6.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

Review 7.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

8.  Clinical use of antidepressant therapy and associated cardiovascular risk.

Authors:  W Stephen Waring
Journal:  Drug Healthc Patient Saf       Date:  2012-08-17

9.  Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010.

Authors:  Christoph Josef Spindelegger; Konstantinos Papageorgiou; Renate Grohmann; Rolf Engel; Waldemar Greil; Anastasios Konstantinidis; Marcus Willy Agelink; Stefan Bleich; Eckart Ruether; Sermin Toto; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

10.  The allometric model in chronic myocardial infarction.

Authors:  Maria P Bonomini; Pedro D Arini; Germán E Gonzalez; Bruno Buchholz; Max E Valentinuzzi
Journal:  Theor Biol Med Model       Date:  2012-05-11       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.